Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | CHIEF REGULATORY OFFICER | June 23, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 53,000 |
Ending reported balance
After 2026-06-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-23 · Exercise / conversion · Acquired 63,000 · Balance 116,000 Row 2 · 2026-06-23 · Sale · Disposed 63,000 · Balance 53,000 F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.08. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2032-08-28 | Direct | 152,250 |
Reported balance
After 2026-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-23 · Exercise / conversion · Disposed 63,000 · Balance 152,250 F3: Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.08. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 140,843 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F3: Includes 481 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.61 · Expires 2024-11-02 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2025-01-20 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2025-11-03 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2026-01-03 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2026-12-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.31 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 33,333 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2030-03-01 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-11-19 · Disposition to issuer · Disposed 15,500 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.41 · Expires 2031-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-11-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: Includes 481 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021
F4: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 23:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001369453-26-000008 · form4-06242026_110649.xml · derivative · entry 3 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,250 Underlying: Class A Common Stock · 63,000 shares Expires 2032-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 63,000 | $6.02 | $379,190.70 |
DisclosureSEC source: 0001369453-26-000008 · form4-06242026_110649.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,000 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.08. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 63,000 | $2.93 | $184,590.00 |
DisclosureSEC source: 0001369453-26-000008 · form4-06242026_110649.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:35 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,750 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001369453-26-000006 · form4-04212026_080412.xml · derivative · entry 3 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,250 Underlying: Class A Common Stock · 36,750 shares Expires 2032-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:35 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 36,750 | $5.01 | $184,279.20 |
DisclosureSEC source: 0001369453-26-000006 · form4-04212026_080412.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,000 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.05. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:35 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 36,750 | $2.93 | $107,677.50 |
DisclosureSEC source: 0001369453-26-000006 · form4-04212026_080412.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:23 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001369453-26-000005 · form4-04082026_080413.xml · derivative · entry 5 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Common Stock · 100,000 shares Expires 2033-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:23 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001369453-26-000005 · form4-04082026_080413.xml · derivative · entry 4 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,000 Underlying: Class A Common Stock · 100,000 shares Expires 2034-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:23 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 200,000 | $4.52 | $903,560.00 |
DisclosureSEC source: 0001369453-26-000005 · form4-04082026_080413.xml · nonDerivative · entry 3 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,000 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $4.44 to $4.64. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:23 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 100,000 | $1.94 | $194,000.00 |
DisclosureSEC source: 0001369453-26-000005 · form4-04082026_080413.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:23 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 100,000 | $1.87 | $187,000.00 |
DisclosureSEC source: 0001369453-26-000005 · form4-04082026_080413.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:02 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 748,130 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001369453-26-000003 · form4-03042026_010334.xml · derivative · entry 2 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,130 Underlying: Class A Common Stock · 748,130 shares Expires 2036-02-26 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:05 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 24,000 | $1.80 | $43,200.00 |
DisclosureSEC source: 0001415889-25-017657 · form4-06182025_040604.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:05 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 26,000 | $1.79 | $46,540.00 |
DisclosureSEC source: 0001415889-25-017657 · form4-06182025_040604.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:37 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001415889-25-006705 · form4-03042025_110318.xml · derivative · entry 1 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:25 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001415889-24-006313 · form4-03042024_100333.xml · derivative · entry 1 Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:57 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001209191-23-014884 · doc4.xml · derivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Class A Common Stock · 400,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 21:18 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 252,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-048156 · doc4.xml · derivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,000 Underlying: Class A Common Stock · 252,000 shares Expires 2032-08-28 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:36 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 247,500 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001209191-22-031879 · doc4.xml · derivative · entry 2 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,500 Underlying: Common Stock · 247,500 shares Expires 2032-05-22 F2 · derivative.exercise_date: The shares subject to the Options will vest based on the satisfaction of both time-based and performance-based vesting criteria. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:36 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 330,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001209191-22-031879 · doc4.xml · derivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2032-05-22 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 5/23/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $11.41 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 11 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-02-28 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 15,500 | Not disclosed Strike: $15.78 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 10 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2030-03-01 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $14.75 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 9 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2029-02-28 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 33,333 | Not disclosed Strike: $22.31 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 8 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2028-01-31 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $18.56 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 7 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2026-12-19 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 6 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-01-03 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $18.16 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 5 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-11-03 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 4 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-01-20 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $19.61 | Not disclosed |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · derivative · entry 3 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2024-11-02 F4 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F4 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 6,000 | $8.50 | $51,000.00 |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 140,843 | $8.50 | $1,197,165.50 |
DisclosureSEC source: 0001209191-21-065709 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F3 · shares: Includes 481 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021 Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 20:49 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,944 | $6.45 | $25,438.80 |
DisclosureSEC source: 0001209191-21-047504 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,362 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit award granted to the Reporting Person on July 16, 2020. F2 · price: The weighted average sale price for the transaction reported was $6.45. The shares were sold at a range of prices between $6.29 and $6.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 21, 2021 Filed Jun 28, 2021 18:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 539 | $7.78 | $4,193.42 |
DisclosureSEC source: 0001209191-21-043523 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,306 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 539 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001209191-21-017271 · doc4.xml · derivative · entry 3 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-28 F2 · derivative.exercise_date: 25% of the shares shall vest on the one-year anniversary of January 1, 2021 (the "Vesting Commencement Date"), and thereafter 1/48th of the total shares shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four years after the Vesting Commencement Date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017271 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,767 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 17:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 6,829 | $11.13 | $76,006.77 |
DisclosureSEC source: 0001209191-21-002565 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,767 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on February 1, 2018, March 1, 2019, and March 2, 2020. F2 · price: The weighted average sale price for the transaction reported was $11.13. The shares were sold at a range of prices between $11.12 and $11.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 416 shares of common stock that were acquired by the Reporting Person on December 20, 2020, at $9.77 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 38,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043107 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,180 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 16:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 369 | $10.83 | $3,996.27 |
DisclosureSEC source: 0001209191-20-038719 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,430 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 369 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:18 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 15,500 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-20-015140 · doc4.xml · derivative · entry 3 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2030-03-01 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:18 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015140 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,061 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 16:33 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002283 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,061 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on February 1, 2018 and March 1, 2019. F2 · price: The shares were sold at a range of prices between $19.73 and $19.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 391 shares of common stock that were acquired by the Reporting Person on December 20, 2019 at $9.89 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 16:27 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 1,002 | $13.98 | $14,007.96 |
DisclosureSEC source: 0001209191-19-052756 · doc4.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,394 Read SEC document |
| October 06, 2019 Filed Oct 8, 2019 16:27 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-052756 · doc4.xml · derivative · entry 4 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,400 shares Expires 2019-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 3,400 shares subject to the restricted stock unit award vested as of October 6, 2019. Read SEC document |
| October 06, 2019 Filed Oct 8, 2019 16:27 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 3,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-052756 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 16:13 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 389 | $9.81 | $3,816.09 |
DisclosureSEC source: 0001209191-19-038761 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,996 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 389 shares by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:18 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 18,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001209191-19-016930 · doc4.xml · derivative · entry 3 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2019 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:18 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016930 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,607 Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 17:10 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 622 | $12.36 | $7,687.92 |
DisclosureSEC source: 0001209191-19-002084 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207 F1 · shares: Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018. F2 · balance_after: Includes 353 shares of common stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 16:30 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 1,002 | $18.60 | $18,637.20 |
DisclosureSEC source: 0001209191-18-054524 · doc4.xml · nonDerivative · entry 1 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,476 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018. Read SEC document |
| October 08, 2018 Filed Mar 5, 2019 20:17 UTC Amendment | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 1,002 | $18.60 | $18,637.20 |
DisclosureSEC source: 0001209191-19-017155 · doc4a.xml · nonDerivative · entry 2 Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,876 F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of the restricted stock unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.